| No | Year of Release | Cord Blood Stored With | Total Nucleated Cell Count | Cord Blood Reinfusion Done in | % of Units Used | Years of Storage | Cord Blood Stored in |
|---|
1 | 2021 | Cryoviva | 107.10 X 1.0E7 | Jul 2021 | 100 % | > 5 Years | Singapore |
2 | 2021 | Cryoviva | 110.30 X 1.0E7 | Jul 2021 | 100% | > 5 Years | Singapore |
The participants were successfully infused with their own cord blood after thorough pre-infusion quality assurance tests and HLA typing had been carried out. All tracked parameters were reported normal one month after infusion, fulfilling the requirements of the trial.
Further details on the outcome of the trial are expected to be released in due course.
Key Questions on the AUCB Clinical Trial
What is the trial’s aim?
To determine if umbilical cord blood stem cells can improve ASD symptoms.
How long is the clinical trial for?
18- 20 months, involving 7 study visits
Who is eligible to participate?
Children aged 24 – 60 months (2- 5 years), who.
hellip;must have been diagnosed with ASD (confirmed clinical DSM-5), and…
…had autologous umbilical cord blood stored with a cord blood bank at the time of birth.
What does the AUCB study entail?
The trial includes the following:
- Two blood tests and a day-care admission to KKH for the reinfusion of the childs cord blood into him/her
- Repeated psychological tests on the child to assess ASD severity, behavior, adaptive skills, and IQ before and after cord blood infusion
- Eye-tracking assessments on the child before and after cord blood infusion
Cryovivas take on the AUCB study
It is heartening to see KKH undertake this clinical trial in Singapore. One in 150 children in Singapore is reported to have this condition. Favourable results on the efficacy of umbilical cord blood infusion for the treatment of autism will be a huge boon to families in Singapore and a source of great hope to them. We eagerly await the complete results of this important trial and wish both KKH and all participants the very best.
Dr Keng Kiat Toh,
Medical Director, Cryoviva
;We are proud to participate in the AUCB study by KKH and are thankful to our valued clients for volunteering themselves as a trial case. As a cord blood bank committed to helping families in Singapore and the region, we consider it our responsibility to contribute in whatever way possible to the advancement of this hugely promising area of healthcare. We are grateful to KKH for this opportunity and hope to be able to be involved with many more such initiatives in the future.”
Rajesh Nair
CEO, Cryoviva Singapore
Note ; Screening slots have all been filled and subject recruitment for this study is now closed.
